James M. Frates - Dec 30, 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Financial Officer
Signature
/s/ James M. Frates
Stock symbol
AMLX
Transactions as of
Dec 30, 2022
Transactions value $
$34,400
Form type
4
Date filed
1/4/2023, 08:33 PM
Previous filing
Jun 17, 2022
Next filing
Jan 10, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Options Exercise $34.4K +5K +15.79% $6.88 36.7K Dec 30, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (Right to Buy) Options Exercise $0 -5K -1.11% $0.00 447K Dec 30, 2022 Common Stock 5K $6.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter.